Vaccination with a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge with a Lethal Dose of Ebola Virus

Demetrius Matassov, Andrea Marzi, Terri Latham, Rong Xu, Ayuko Ota-Setlik, Friederike Feldmann, Joan B. Geisbert, Chad Mire, Stefan Hamm, Becky Nowak, Michael A. Egan, Thomas Geisbert, John H. Eldridge, Heinz Feldmann, David K. Clarke

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Previously, recombinant vesicular stomatitis virus (rVSV) pseudotypes expressing Ebolavirus glycoproteins (GPs) in place of the VSV G protein demonstrated protection of nonhuman primates from lethal homologous Ebolavirus challenge. Those pseudotype vectors contained no additional attenuating mutations in the rVSV genome. Here we describe rVSV vectors containing a full complement of VSV genes and expressing the Ebola virus (EBOV) GP from an additional transcription unit. These rVSV vectors contain the same combination of attenuating mutations used previously in the clinical development pathway of an rVSV/human immunodeficiency virus type 1 vaccine. One of these rVSV vectors (N4CT1-EBOVGP1), which expresses membrane-anchored EBOV GP from the first position in the genome (GP1), elicited a balanced cellular and humoral GP-specific immune response in mice. Guinea pigs immunized with a single dose of this vector were protected from any signs of disease following lethal EBOV challenge, while control animals died in 7-9 days. Subsequently, N4CT1-EBOVGP1 demonstrated complete, single-dose protection of 2 macaques following lethal EBOV challenge. A single sham-vaccinated macaque died from disease due to EBOV infection. These results demonstrate that highly attenuated rVSV vectors expressing EBOV GP may provide safer alternatives to current EBOV vaccines.

Original languageEnglish (US)
Pages (from-to)S443-S451
JournalJournal of Infectious Diseases
Volume212
DOIs
StatePublished - Oct 1 2015

Fingerprint

Ebolavirus
Vesicular Stomatitis
Vaccination
Viruses
Glycoproteins
Macaca
Ebola Vaccines
Ebola Hemorrhagic Fever
Genome
Mutation
Critical Pathways
GTP-Binding Proteins
Primates
HIV-1
Guinea Pigs
Vaccines
Membranes

Keywords

  • attenuation
  • challenge
  • Ebola vaccine
  • glycoprotein
  • nonhuman primates
  • rVSV vector

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

Vaccination with a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge with a Lethal Dose of Ebola Virus. / Matassov, Demetrius; Marzi, Andrea; Latham, Terri; Xu, Rong; Ota-Setlik, Ayuko; Feldmann, Friederike; Geisbert, Joan B.; Mire, Chad; Hamm, Stefan; Nowak, Becky; Egan, Michael A.; Geisbert, Thomas; Eldridge, John H.; Feldmann, Heinz; Clarke, David K.

In: Journal of Infectious Diseases, Vol. 212, 01.10.2015, p. S443-S451.

Research output: Contribution to journalArticle

Matassov, D, Marzi, A, Latham, T, Xu, R, Ota-Setlik, A, Feldmann, F, Geisbert, JB, Mire, C, Hamm, S, Nowak, B, Egan, MA, Geisbert, T, Eldridge, JH, Feldmann, H & Clarke, DK 2015, 'Vaccination with a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge with a Lethal Dose of Ebola Virus', Journal of Infectious Diseases, vol. 212, pp. S443-S451. https://doi.org/10.1093/infdis/jiv316
Matassov, Demetrius ; Marzi, Andrea ; Latham, Terri ; Xu, Rong ; Ota-Setlik, Ayuko ; Feldmann, Friederike ; Geisbert, Joan B. ; Mire, Chad ; Hamm, Stefan ; Nowak, Becky ; Egan, Michael A. ; Geisbert, Thomas ; Eldridge, John H. ; Feldmann, Heinz ; Clarke, David K. / Vaccination with a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge with a Lethal Dose of Ebola Virus. In: Journal of Infectious Diseases. 2015 ; Vol. 212. pp. S443-S451.
@article{b951baafc998429ab4854a10cdd89c25,
title = "Vaccination with a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge with a Lethal Dose of Ebola Virus",
abstract = "Previously, recombinant vesicular stomatitis virus (rVSV) pseudotypes expressing Ebolavirus glycoproteins (GPs) in place of the VSV G protein demonstrated protection of nonhuman primates from lethal homologous Ebolavirus challenge. Those pseudotype vectors contained no additional attenuating mutations in the rVSV genome. Here we describe rVSV vectors containing a full complement of VSV genes and expressing the Ebola virus (EBOV) GP from an additional transcription unit. These rVSV vectors contain the same combination of attenuating mutations used previously in the clinical development pathway of an rVSV/human immunodeficiency virus type 1 vaccine. One of these rVSV vectors (N4CT1-EBOVGP1), which expresses membrane-anchored EBOV GP from the first position in the genome (GP1), elicited a balanced cellular and humoral GP-specific immune response in mice. Guinea pigs immunized with a single dose of this vector were protected from any signs of disease following lethal EBOV challenge, while control animals died in 7-9 days. Subsequently, N4CT1-EBOVGP1 demonstrated complete, single-dose protection of 2 macaques following lethal EBOV challenge. A single sham-vaccinated macaque died from disease due to EBOV infection. These results demonstrate that highly attenuated rVSV vectors expressing EBOV GP may provide safer alternatives to current EBOV vaccines.",
keywords = "attenuation, challenge, Ebola vaccine, glycoprotein, nonhuman primates, rVSV vector",
author = "Demetrius Matassov and Andrea Marzi and Terri Latham and Rong Xu and Ayuko Ota-Setlik and Friederike Feldmann and Geisbert, {Joan B.} and Chad Mire and Stefan Hamm and Becky Nowak and Egan, {Michael A.} and Thomas Geisbert and Eldridge, {John H.} and Heinz Feldmann and Clarke, {David K.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1093/infdis/jiv316",
language = "English (US)",
volume = "212",
pages = "S443--S451",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Vaccination with a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge with a Lethal Dose of Ebola Virus

AU - Matassov, Demetrius

AU - Marzi, Andrea

AU - Latham, Terri

AU - Xu, Rong

AU - Ota-Setlik, Ayuko

AU - Feldmann, Friederike

AU - Geisbert, Joan B.

AU - Mire, Chad

AU - Hamm, Stefan

AU - Nowak, Becky

AU - Egan, Michael A.

AU - Geisbert, Thomas

AU - Eldridge, John H.

AU - Feldmann, Heinz

AU - Clarke, David K.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Previously, recombinant vesicular stomatitis virus (rVSV) pseudotypes expressing Ebolavirus glycoproteins (GPs) in place of the VSV G protein demonstrated protection of nonhuman primates from lethal homologous Ebolavirus challenge. Those pseudotype vectors contained no additional attenuating mutations in the rVSV genome. Here we describe rVSV vectors containing a full complement of VSV genes and expressing the Ebola virus (EBOV) GP from an additional transcription unit. These rVSV vectors contain the same combination of attenuating mutations used previously in the clinical development pathway of an rVSV/human immunodeficiency virus type 1 vaccine. One of these rVSV vectors (N4CT1-EBOVGP1), which expresses membrane-anchored EBOV GP from the first position in the genome (GP1), elicited a balanced cellular and humoral GP-specific immune response in mice. Guinea pigs immunized with a single dose of this vector were protected from any signs of disease following lethal EBOV challenge, while control animals died in 7-9 days. Subsequently, N4CT1-EBOVGP1 demonstrated complete, single-dose protection of 2 macaques following lethal EBOV challenge. A single sham-vaccinated macaque died from disease due to EBOV infection. These results demonstrate that highly attenuated rVSV vectors expressing EBOV GP may provide safer alternatives to current EBOV vaccines.

AB - Previously, recombinant vesicular stomatitis virus (rVSV) pseudotypes expressing Ebolavirus glycoproteins (GPs) in place of the VSV G protein demonstrated protection of nonhuman primates from lethal homologous Ebolavirus challenge. Those pseudotype vectors contained no additional attenuating mutations in the rVSV genome. Here we describe rVSV vectors containing a full complement of VSV genes and expressing the Ebola virus (EBOV) GP from an additional transcription unit. These rVSV vectors contain the same combination of attenuating mutations used previously in the clinical development pathway of an rVSV/human immunodeficiency virus type 1 vaccine. One of these rVSV vectors (N4CT1-EBOVGP1), which expresses membrane-anchored EBOV GP from the first position in the genome (GP1), elicited a balanced cellular and humoral GP-specific immune response in mice. Guinea pigs immunized with a single dose of this vector were protected from any signs of disease following lethal EBOV challenge, while control animals died in 7-9 days. Subsequently, N4CT1-EBOVGP1 demonstrated complete, single-dose protection of 2 macaques following lethal EBOV challenge. A single sham-vaccinated macaque died from disease due to EBOV infection. These results demonstrate that highly attenuated rVSV vectors expressing EBOV GP may provide safer alternatives to current EBOV vaccines.

KW - attenuation

KW - challenge

KW - Ebola vaccine

KW - glycoprotein

KW - nonhuman primates

KW - rVSV vector

UR - http://www.scopus.com/inward/record.url?scp=84943247048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943247048&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiv316

DO - 10.1093/infdis/jiv316

M3 - Article

VL - 212

SP - S443-S451

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

ER -